GSK, Arexvy
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case for its first-to-market respiratory syncytial virus (RSV) shot Arexvy. | GSK on Tuesday unveiled fresh data from the late-stage AReSVi-006 study of Arexvy in RSV-triggered lower respiratory tract disease in older adults over the span of three full RSV seasons.
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating
GSK's Arexvy provides protection over three RSV seasons, trial shows
GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01E adjuvant.
GSK Says RSV Vaccine Arexvy Showed Positive Efficacy Data Over Three Seasons
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
McKnight's Long-Term Care News2h
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...
ENDPOINTS NEWS3h
GSK's RSV vac­cine Arexvy shows long-term pro­tec­tion in Phase 3 tri­al
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...